Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor

mAbs

Volumn 6, Issue 4, 2014, Pages 1013-1025

  Tundidor, Yaima ^a   Garciá Hernández, Claudia Patricia ^a   Pupo, Amaury ^a   Infante, Yanelys Cabrera ^a   Rojas, Gertrudis ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Epitope mapping; Molecular modeling; Paratope; Phage display; Site directed mutagenesis

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; IMMUNOGLOBULIN HEAVY CHAIN; NIMOTUZUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY ENGINEERING; ANTIGEN RECOGNITION; ARTICLE; CHEMOSENSITIVITY; COMBINATORIAL LIBRARY; COMPUTER MODEL; CONTROLLED STUDY; DRUG BINDING SITE; DRUG TARGETING; HUMAN; PHAGE DISPLAY; PROTEIN DOMAIN; SITE DIRECTED MUTAGENESIS; ANTIBODY SPECIFICITY; CHEMISTRY; EPITOPE MAPPING; PROCEDURES; PROTEIN TERTIARY STRUCTURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY SPECIFICITY; EPITOPE MAPPING; EPITOPES; HUMANS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84903778160     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28915     Document Type: Article

References (58)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073
3. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006; 312:1175-8; PMID:16728632; http://dx.doi.org/10.1126/science.1125951
4. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931
5. Fernandez A, Spitzer E, Perez R, Boehmer FD, Eckert K, Zschiesche W, Grosse R. A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections. J Cell Biochem 1992; 49:157-65; PMID:1400622; http://dx.doi.org/10.1002/jcb.240490208
6. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71-81; PMID:9154469; http://dx.doi.org/10.1016/S1380-2933(97)00065-1
7. Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9:343-9; PMID:20448462; http://dx.doi.org/10.4161/cbt.9.5.10981
8. Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domíngez R, Alert J, Marinello JJ, et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 2013; 13:299; PMID:23782513; http://dx.doi.org/10.1186/1471-2407-13-299
9. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YA, Moreno BP, Alvarez ES, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized antiepidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 2012; 13:600-5; PMID:22555809; http://dx.doi.org/10.4161/cbt.19849
10. Boland W, Bebb G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics 2010; 4:289-98; PMID:21116327
11. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2012; 30:1138-43; PMID:21170759; http://dx.doi.org/10.1007/s10637-010-9619-8
12. Allan DGP. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005; 10:760-1; PMID:16249358; http://dx.doi.org/10.1634/ theoncologist.10-9-760
13. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567-75; PMID:12237899; http://dx.doi.org/10.1002/ijc.10647
14. Diaz Miqueli A, Blanco R, Garcia B, Badia T, Batista AE, Alonso R, Montero E. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 2007; 26:423-31; PMID:18158788; http://dx.doi.org/10.1089/hyb.2007.0516
15. Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, López-Requena A, Pupo A, Johansen RF, Sánchez O, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69:5851-9; PMID:19584289; http://dx.doi.org/10. 1158/0008-5472.CAN-08-4518
16. Chao G, Cochran JR, Wittrup KD. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol 2004; 342:539-50; PMID:15327953; http://dx.doi.org/10.1016/ j.jmb.2004.07.053
17. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; http://dx.doi.org/10.1016/ j.ccr.2005.03.003
18. Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008; 16:216-27; PMID:18275813; http://dx.doi.org/10.1016/j.str.2007.11.009
19. Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, Cocklin S, Williams JC, Papazoglou E, Rodeck U. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 2008; 7:726-33; PMID:18424917; http://dx.doi.org/10.4161/cbt.7.5.6097
20. Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011; 3:584-95; PMID:22123060; http://dx.doi.org/10.4161/ mabs.3.6.17955
21. Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, Binder M. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 2012; 14:1023-31; PMID:23226096
22. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18:221-3; PMID:22270724; http://dx.doi.org/10.1038/nm.2609
23. Ramírez BS, Pestana ES, Hidalgo GG, García TH, Rodríguez RP, Ullrich A, Férnandez LE. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer 2006; 119:2190-9; PMID:16841332; http://dx.doi.org/10.1002/ijc.22085
24. Cochran JR, Kim Y-S, Olsen MJ, Bhandari R, Wittrup KD. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods 2004; 287:147-58; PMID:15099763; http://dx.doi.org/10.1016/j.jim.2004.01.024
25. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983; 1:511-29; PMID:6094961
26. Van den Burg B, Dijkstra BW, Vriend G, Van der Vinne B, Venema G, Eijsink VG. Protein stabilization by hydrophobic interactions at the surface. Eur J Biochem 1994; 220:981-5; PMID:8143751; http://dx.doi.org/10.1111/j.1432-1033. 1994.tb18702.x
27. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775-87; PMID:12297050; http://dx.doi.org/10.1016/S0092-8674(02)00963-7
28. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110:763-73; PMID:12297049; http://dx.doi.org/10. 1016/S0092-8674(02)00940-6
29. Rojas G, Pupo A, Leon K, Avellanet J, Carmenate T, Sidhu S. Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping. Immunobiology 2013; 218:105-13; PMID:22459271; http://dx.doi.org/10.1016/j.imbio.2012.02.009
30. Rojas G, Cabrera Infante Y, Pupo A, Carmenate T. Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effects. MAbs 2014; 6:273-85; PMID:24253188; http://dx.doi.org/10.4161/mabs. 27224
31. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924-7; PMID:16484453; http://dx.doi.org/10.1126/science.1122927
32. Klein C, Lammens A, Schafer W, Georges G, Schwaiger M. mossner, E., Hopfner, K.P., Umaña, P. & Niederfellner, G. Epitope interactions of monoclonal antibodies targeting CD20 and their relationships to functional properties. MAbs 2013; 5:1-12; PMID:23254906; http://dx.doi.org/10.4161/mabs. 22771
33. Davies DR, Cohen GH. Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A 1996; 93:7-12; PMID:8552677; http://dx.doi.org/10.1073/ pnas.93.1.7
34. Benjamin DC, Perdue SS. Site-directed mutagenesis in epitope mapping. Methods 1996; 9:508-15; PMID:8812706; http://dx.doi.org/10.1006/meth.1996.0058
35. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A 2010; 107:13252-7; PMID:20616078; http://dx.doi.org/10.1073/pnas.0913476107
36. Hartmann C, Müller N, Blaukat A, Koch J, Benhar I, Wels WS. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 2010; 29:4517-27; PMID:20514015; http://dx.doi.org/10.1038/onc.2010.195
37. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced antiepidermal growth factor receptor antibodies. J Natl Cancer Inst 2005; 97:1663-70; PMID:16288119; http://dx.doi.org/10.1093/jnci/dji373
38. Cardó-Vila M, Giordano RJ, Sidman RL, Bronk LF, Fan Z, Mendelsohn J, Arap W, Pasqualini R. From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway. Proc Natl Acad Sci U S A 2010; 107:5118-23; PMID:20190183; http://dx.doi.org/10.1073/pnas. 0915146107
39. Smith GP, Petrenko VA. Phage Display. Chem Rev 1997; 97:391-410; PMID:11848876; http://dx.doi.org/10.1021/cr960065d
40. Berger C, Krengel U, Stang E, Moreno E, Madshus IH. Nimotuzumab and cetuximab block ligandindependent EGF receptor signaling efficiently at different concentrations. J Immunother 2011; 34:550-5; PMID:21760527; http://dx.doi.org/10.1097/CJI.0b013e31822a5ca6
41. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646-54; PMID:15117987; http://dx.doi.org/10.1200/JCO.2004.03.089
42. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11:373-82; PMID:21150278; http://dx.doi.org/10.4161/cbt.11.4.14097
43. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5; PMID:16618717; http://dx.doi.org/10.1158/0008-5472.CAN-06-0191
44. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
45. Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 2010; 9:315-8; PMID:21208847; http://dx.doi.org/10.3816/CCC. 2010.n.046
46. Sonoda H, Mekata E, Shimizu T, Endo Y, Tani T. Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution. Oncol Lett 2013; 5:1331-4; PMID:23599789
47. Rojas G, Pupo A, Gómez S, Krengel U, Moreno E. Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificities. ACS Chem Biol 2013; 8:376-86; PMID:23138862; http://dx.doi.org/10.1021/cb3003754
48. Lamdan H, Gavilondo JV, Muñoz Y, Pupo A, Huerta V, Musacchio A, Pérez L, Ayala M, Rojas G, Balint RF, et al. Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor. Mol Biosyst 2013; 9:2097-106; PMID:23702826; http://dx.doi.org/10.1039/c3mb70136k
49. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-4; PMID:19299620; http://dx.doi.org/10.1126/science.1165480
50. Chaudhury S, Berrondo M, Weitzner BD, Muthu P, Bergman H, Gray JJ. Benchmarking and analysis of protein docking performance in Rosetta v3.2. PLoS One 2011; 6:e22477; PMID:21829626; http://dx.doi.org/10.1371/journal.pone. 0022477
51. Lee M, Lloyd P, Zhang X, Schallhorn JM, Sugimoto K, Leach AG, Sapiro G, Houk KN. Shapes of antibody binding sites: qualitative and quantitative analyses based on a geomorphic classification scheme. J Org Chem 2006; 71:5082-92; PMID:16808494; http://dx.doi.org/10.1021/jo052659z
52. Vercruysse T, Boons E, Venken T, Vanstreels E, Voet A, Steyaert J, De Maeyer M, Daelemans D. Mapping the binding interface between an HIV-1 inhibiting intrabody and the viral protein Rev. PLoS One 2013; 8:e60259; PMID:23565213; http://dx.doi.org/10.1371/journal.pone.0060259
53. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581-97; PMID:1748994; http://dx.doi.org/10.1016/ 0022-2836(91)90498-U
54. Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A 1985; 82:488-92; PMID:3881765; http://dx.doi.org/10.1073/pnas.82.2.488
55. Rojas G. Fine epitope mapping based on phage display and extensive mutagenesis of the target antigen. Methods Mol Biol 2014; 1131:447-76; PMID:24515482; http://dx.doi.org/10.1007/978-1-62703-992-5-27
56. Fellouse FA, Sidhu SS. Making antibodies in bacteria. In Making and using antibodies. A practical handbook 2007. G.C. Howard, and M.R.Kaser, CRC Press, Boca Raton, Florida, pp 157-177.
57. Gray JJ, Moughon S, Wang C, Schueler-Furman O, Kuhlman B, Rohl CA, Baker D. Protein-protein docking with simultaneous optimization of rigidbody displacement and side-chain conformations. J Mol Biol 2003; 331:281-99; PMID:12875852; http://dx.doi.org/10.1016/S0022-2836(03)00670-3
58. Kellogg EH, Leaver-Fay A, Baker D. Role of conformational sampling in computing mutation-induced changes in protein structure and stability. Proteins 2011; 79:830-8; PMID:21287615; http://dx.doi.org/10.1002/prot.22921